TARGET AUDIENCE
This activity is intended for medical, radiation and thoracic oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

OVERVIEW OF ACTIVITY
The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Perhaps the most exciting arena in this regard has been the development and assessment of a class of checkpoint inhibitors that inhibit PD-1 or PD-L1. To date, studies with these agents in NSCLC have demonstrated a high degree of activity with limited toxicity in the metastatic and, more recently, locally advanced settings. The availability of these novel compounds has rapidly upended traditional therapeutic sequencing and caused both shifts and rifts in clinical management algorithms, and a number of controversies and questions remain with regard to the current application of these agents in clinical practice.

These video proceedings from a CME symposium held during the 2017 IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology feature discussions with leading researchers with an expertise in lung cancer. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical, radiation and thoracic oncologists and other healthcare providers with the optimal incorporation of immune checkpoint inhibitors in NSCLC.

LEARNING OBJECTIVES

• Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational anti-PD-1/PD-L1 antibodies for the treatment of NSCLC to determine the current and/or potential utility of each in clinical practice.
• Review published research data documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
• Appraise emerging research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable Stage III NSCLC whose disease has not progressed after standard platinum-based chemotherapy concurrent with radiation therapy.
• Recognize immune-related adverse events and other common side effects associated with the use of approved and developmental immune checkpoint inhibitors, and offer supportive management strategies to minimize and/or manage these toxicities.
• Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches alone or in combination with other systemic therapies, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

MODERATOR
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Ariad Pharmaceuticals Inc, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc.

FACULTY
Nasser H Hanna, MD
Professor of Medicine
Indiana University
Indianapolis, Indiana

Contracted Research: Bristol-Myers Squibb Company, Merck.

Leora Horn, MD, MSc
Associate Professor of Medicine
Clinical Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Advisory Committee: AbbVie Inc, Genentech BioOncology, Merck; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly, Xcovery; Paid Travel: Boehringer Ingelheim Pharmaceuticals Inc.

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: October 2017
Expiration date: October 2018